Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 683

1.

Differential effects of vitamin D receptor activators on aortic calcification and pulse wave velocity in uraemic rats.

Noonan W, Koch K, Nakane M, Ma J, Dixon D, Bolin A, Reinhart G.

Nephrol Dial Transplant. 2008 Dec;23(12):3824-30. doi: 10.1093/ndt/gfn375. Epub 2008 Jul 20.

PMID:
18644798
2.

Differential effects of vitamin D receptor activators on vascular calcification in uremic rats.

Mizobuchi M, Finch JL, Martin DR, Slatopolsky E.

Kidney Int. 2007 Sep;72(6):709-15. Epub 2007 Jun 27.

3.

Differential effects of vitamin D analogs on vascular calcification.

Cardús A, Panizo S, Parisi E, Fernandez E, Valdivielso JM.

J Bone Miner Res. 2007 Jun;22(6):860-6.

4.

Differential effects of very high doses of doxercalciferol and paricalcitol on serum phosphorus in hemodialysis patients.

Joist HE, Ahya SN, Giles K, Norwood K, Slatopolsky E, Coyne DW.

Clin Nephrol. 2006 May;65(5):335-41.

PMID:
16724654
5.

Effect of 2-methylene-19-nor-(20S)-1 alpha-hydroxy-bishomopregnacalciferol (2MbisP), an analog of vitamin D, on secondary hyperparathyroidism.

Slatopolsky E, Finch JL, Brown AJ, Ritter CS, Mizobuchi M, Plum LA, Clagett-Dame M, Sicinski RR, DeLuca HF.

J Bone Miner Res. 2007 May;22(5):686-94.

6.

Up-regulation of Cbfa1 and Pit-1 in calcified artery of uraemic rats with severe hyperphosphataemia and secondary hyperparathyroidism.

Mizobuchi M, Ogata H, Hatamura I, Koiwa F, Saji F, Shiizaki K, Negi S, Kinugasa E, Ooshima A, Koshikawa S, Akizawa T.

Nephrol Dial Transplant. 2006 Apr;21(4):911-6. Epub 2005 Dec 29.

PMID:
16384827
8.

Oral paricalcitol for the treatment of secondary hyperparathyroidism in patients on hemodialysis or peritoneal dialysis.

Ross EA, Tian J, Abboud H, Hippensteel R, Melnick JZ, Pradhan RS, Williams LA, Hamm LL, Sprague SM.

Am J Nephrol. 2008;28(1):97-106. Epub 2007 Oct 3.

PMID:
17914251
9.

Vascular calcification in chronic kidney failure: role of vitamin D receptor.

Wu-Wong JR, Melnick J.

Curr Opin Investig Drugs. 2007 Mar;8(3):237-47. Review.

PMID:
17408120
10.

Suppression of parathyroid hormone secretion in hemodialysis patients by a novel vitamin D analogue: 19-nor-1,25-dihydroxyvitamin D2.

Llach F, Keshav G, Goldblat MV, Lindberg JS, Sadler R, Delmez J, Arruda J, Lau A, Slatopolsky E.

Am J Kidney Dis. 1998 Oct;32(2 Suppl 2):S48-54.

PMID:
9808143
11.
12.

Emerging role for the vitamin D receptor activator (VDRA), paricalcitol, in the treatment of secondary hyperparathyroidism.

Cozzolino M, Brancaccio D.

Expert Opin Pharmacother. 2008 Apr;9(6):947-54. doi: 10.1517/14656566.9.6.947. Review.

PMID:
18377338
13.

Mapping the time-dependent effects of paricalcitol on serum calcium, phosphorus and parathyroid hormone levels in 5/6 nephrectomized uremic rats.

Wu-Wong JR, Nakane M, Chen YW.

Life Sci. 2013 Feb 7;92(2):161-6. doi: 10.1016/j.lfs.2012.11.018. Epub 2012 Dec 19.

PMID:
23261531
14.

The effects of sevelamer hydrochloride and calcium carbonate on kidney calcification in uremic rats.

Cozzolino M, Dusso AS, Liapis H, Finch J, Lu Y, Burke SK, Slatopolsky E.

J Am Soc Nephrol. 2002 Sep;13(9):2299-308.

15.

Doxercalciferol safely suppresses PTH levels in patients with secondary hyperparathyroidism associated with chronic kidney disease stages 3 and 4.

Coburn JW, Maung HM, Elangovan L, Germain MJ, Lindberg JS, Sprague SM, Williams ME, Bishop CW.

Am J Kidney Dis. 2004 May;43(5):877-90.

PMID:
15112179
16.

Role of phosphorus and vitamin D analogs in the pathogenesis of vascular calcification.

Wu-Wong JR, Noonan W, Ma J, Dixon D, Nakane M, Bolin AL, Koch KA, Postl S, Morgan SJ, Reinhart GA.

J Pharmacol Exp Ther. 2006 Jul;318(1):90-8. Epub 2006 Apr 7.

17.
18.

Sevelamer hydrochloride attenuates kidney and cardiovascular calcifications in long-term experimental uremia.

Cozzolino M, Staniforth ME, Liapis H, Finch J, Burke SK, Dusso AS, Slatopolsky E.

Kidney Int. 2003 Nov;64(5):1653-61.

19.

Effects of new vitamin D analogues on parathyroid function in chronically uraemic rats with secondary hyperparathyroidism.

Hruby M, Ureña P, Mannstadt M, Schmitt F, Lacour B, Drüeke TB.

Nephrol Dial Transplant. 1996 Sep;11(9):1781-6.

PMID:
8918622
20.

Systemic cardiovascular disease in uremic rats induced by 1,25(OH)2D3.

Haffner D, Hocher B, Müller D, Simon K, König K, Richter CM, Eggert B, Schwarz J, Godes M, Nissel R, Querfeld U.

J Hypertens. 2005 May;23(5):1067-75.

PMID:
15834294

Supplemental Content

Support Center